Our business model is based on:

  • Developing patented drug development candidates that can extend life and reduce care costs, for sale to the international pharmaceutical industry for further clinical trials.
  • Developing and licensing out drug candidates in return for payments made upfront and on reaching milestones in product development (typically at the start of clinical phases I, II and III and on filing), with additional royalty revenues.